SCHEMBL353534

SCHEMBL353534

Cc1cc(O)c2ccccc2c1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.63
LMNA P02545 1/20 0.63
EP300 Q09472 2/20 0.58
MAPT P10636 4/20 0.49
KDM4E B2RXH2 3/20 0.49
GAA P10253 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TP53 P04637 1/20 0.49
PKM P14618 2/20 0.48
IDO1 P14902 2/20 0.45
HDAC3 O15379 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT8 Q9H7Z6 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
TRPM4 Q8TD43 1/20 0.45
MEN1 O00255 1/20 0.41
NSD2 O96028 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1648808 0.98 HTT (0.61) HTTLMNAEP300MAPTKDM4E
SCHEMBL29462977 0.79 CYP1A2 (0.43) HTTLMNAEP300KDM4EGAA
SCHEMBL1562090 0.79 CYP1A2 (0.50) LMNAEP300KDM4EGAAHSD17B10
SCHEMBL29999289 0.79 CYP1A2 (0.50) LMNAEP300KDM4EGAAHSD17B10
SCHEMBL866443 0.79 CYP1A2 (0.43) HTTLMNAEP300KDM4EGAA
SCHEMBL352532 0.77 PKM (0.63) HTTLMNAEP300MAPTKDM4E
Vitamin K3H2 SCHEMBL297164 0.77 HTT (1.00) HTTLMNAEP300MAPTKDM4E
Vitamin K3H2 SCHEMBL29525544 0.77 HTT (1.00) HTTLMNAEP300MAPTKDM4E
SCHEMBL4631028 0.77 HTT (0.68) HTTLMNAEP300MAPTKDM4E
SCHEMBL29405295 0.77 PKM (0.63) HTTLMNAEP300MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724104-A1 SYNERGISTIC COMPOSITION FOR ENHANCING THE SOLUBILITY, STABILITY, BIOAVAILABILTY AND IMMEDIATE RELEASE OF ACTIVE COMPOUNDS Olene Life Sciences Private Limited (IN) 2026-04-15 EP claimed
US-20250034321-A1 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES EVONIK OPERATIONS GMBH (DE) 2025-01-30 US claimed
EP-4413058-A1 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES Evonik Operations GmbH (DE) 2024-08-14 EP claimed
CN-118055962-A Epoxy curing agent composition comprising naphthol and naphthol derivative 赢创运营有限公司 2024-05-17 CN claimed
WO-2023057234-A9 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES EVONIK OPERATIONS GMBH (DE) 2024-05-10 WO claimed
WO-2023057234-A1 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES EVONIK OPERATIONS GMBH (DE) 2023-04-13 WO claimed
CN-115067522-A Choline-containing multivitamin and mineral composition and preparation method and application thereof 养生堂药业有限公司 2022-09-20 CN claimed
US-20220218781-A1 COMPOSITION FOR ENHANCEMENT OF BIOAVAILABILITY OF PHYTOCHEMICALS AND PROCESS FOR PREPARATION THEREOF OLENE LIFE SCIENCES PRIVATE LIMITED (IN) 2022-07-14 US claimed
EP-4724104-A1 SYNERGISTIC COMPOSITION FOR ENHANCING THE SOLUBILITY, STABILITY, BIOAVAILABILTY AND IMMEDIATE RELEASE OF ACTIVE COMPOUNDS Olene Life Sciences Private Limited (IN) 2026-04-15 EP disclosed
CN-118924714-B MK-7-containing pharmaceutical composition, application and preparation method thereof 广东新达瑞生物科技有限公司 2025-04-11 CN disclosed
WO-2025062177-A1 SYNERGISTIC COMPOSITIONS OF SOLANUM LYCOPERSICUM L. EXTRACTS AND SELENIUM (SE), USEFUL FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. CENTRO DE INVESTIGACIÓN Y DE ESTUDIOS AVANZADOS DEL I.P.N. (MX) 2025-03-27 WO disclosed
US-12226484-B2 Compositions having improved bioavailability of therapeutics TRx Biosciences Limited (GB) 2025-02-18 US disclosed
US-20250034321-A1 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES EVONIK OPERATIONS GMBH (DE) 2025-01-30 US disclosed
EP-3177275-B1 COMPOSITION COMPRISING HYDROPHOBIC BIOLOGICALLY ACTIVE COMPOUNDS AND METHOD FOR PREPARING SAID COMPOSITION ADVANCED BIONUTRITION CORP (US) 2024-10-23 EP disclosed
WO-2000078278-A1 ANHYDROUS ULTRAVIOLET LIGHT SCREENING COMPOSITION CONTAINING OCTOCRYLENE SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 2000-12-28 WO disclosed
EP-1060735-A1 Anhydrous ultraviolet light screening composition containing octocrylene SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 2000-12-20 EP disclosed
EP-0117321-B1 FOODSTUFFS, INCLUDING CHEWING GUM WITH ANTI-CARIES ACTIVITY, AND PROCESSES FOR PREPARING THEM TABAGH AG (CH) 1991-07-24 EP disclosed
EP-0117321-A2 Foodstuffs, including chewing gum with anti-caries activity, and processes for preparing them TABAGH AG (CH) 1984-09-05 EP disclosed
US-4332884-A USING A DIOXIME CHELATING AGENT RICOH CO., LTD. (JP) 1982-06-01 US disclosed
US-4306014-A AMMONIA OR AMINES SUPPRESS THE COLOR-FORMING REACTION SYSTEM RICOH CO., LTD. (JP) 1981-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034321-A1 COMPOSITIONS OF EPOXY CURING AGENT INCORPORATING NAPHTHOL AND NAPHTHOL DERIVATIVES SRM, PNMT, NIT2 HTT 1810/4885LMNA 518/4885EP300 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.